Mechanism of E. coli colonization resistance

大肠杆菌定植抗性机制

基本信息

  • 批准号:
    8902448
  • 负责人:
  • 金额:
    $ 38.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-20 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The gastrointestinal tract is host to a dense microbial community, known as the gut microbiota, which is dominated by obligate anaerobic bacteria belonging to the phyla Bacteroidetes (class Bacteroidia) and Firmicutes (class Clostridia). This microbial community offers benefit by conferring niche protection against facultative anaerobic Proteobacteria (e.g. Escherichia coli), a property known as 'colonization resistance'. However, the precise mechanisms by which the gut microbiota confers colonization resistance remain obscure. The objectives of this application are to study how the gut microbiota influences colonization resistance against Proteobacteria, using E. coli as a prototypical representative. Our central hypothesis is that obligate anaerobic bacteria mediate colonization resistance against E. coli through microbe-host interactions that suppress inflammation. Disruption of these microbe-host interactions by antibiotic treatment (dysbiosis) increases the inflammatory tone of the intestinal mucosa and the concomitant production of radicals by the host response generates respiratory electron acceptors, which support growth of E. coli by anaerobic respiration. In Aim 1 we will determine whether a reduction in short-chain fatty acid (SCFA) concentrations after antibiotic treatment is responsible for lowering colonization resistance against E. coli. In Aim 2 we will develop approaches to treat dysbiosis induced by antibiotic therapy. Successful completion of our study will provide innovation by establishing a novel mechanism for colonization resistance (Aim 1) and facilitating the development of approaches to treat a loss of colonization resistance when a balanced community has been disrupted (Aim 2). This outcome will be significant because conceptual advances resulting from the proposed work are expected to establish a new paradigm that will influence research by others in the field.
描述(由申请人提供):胃肠道是一个密集的微生物群落的宿主,称为肠道微生物群,其中以属于拟杆菌门(拟杆菌类)和厚壁菌门(梭状芽胞杆菌类)的专性厌氧细菌为主。该微生物群落通过提供针对兼性厌氧变形菌(例如大肠杆菌)的生态位保护来提供益处,这种特性被称为“定植抗性”。然而,肠道微生物群赋予定植抵抗力的确切机制仍然不清楚。本申请的目的是使用大肠杆菌作为典型代表,研究肠道微生物群如何影响变形菌的定植抗性。我们的中心假设是,专性厌氧细菌通过抑制炎症的微生物-宿主相互作用介导对大肠杆菌的定植抵抗力。通过抗生素治疗(生态失调)破坏这些微生物与宿主的相互作用,会增加肠粘膜的炎症张力,并且宿主反应会产生自由基,从而产生呼吸电子受体,从而通过无氧呼吸支持大肠杆菌的生长。在目标 1 中,我们将确定抗生素治疗后短链脂肪酸 (SCFA) 浓度的降低是否会降低大肠杆菌的定植耐药性。在目标 2 中,我们将开发治疗抗生素治疗引起的生态失调的方法。我们的研究的成功完成将通过建立一种新颖的定植抵抗机制(目标 1)并促进开发在平衡的群落被破坏时治疗定植抵抗力丧失的方法(目标 2)来提供创新。这一结果将意义重大,因为拟议工作带来的概念进步预计将建立一个新的范式,从而影响该领域其他人的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andreas J Baumler其他文献

Andreas J Baumler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andreas J Baumler', 18)}}的其他基金

Citrobacter illuminates the mechanistic underpinnings of gut biogeography
柠檬酸杆菌阐明了肠道生物地理学的机制基础
  • 批准号:
    10198730
  • 财政年份:
    2020
  • 资助金额:
    $ 38.16万
  • 项目类别:
Citrobacter illuminates the mechanistic underpinnings of gut biogeography
柠檬酸杆菌阐明了肠道生物地理学的机制基础
  • 批准号:
    10027725
  • 财政年份:
    2020
  • 资助金额:
    $ 38.16万
  • 项目类别:
Dietary copper reconfigures pathogen growth
膳食铜重新配置病原体生长
  • 批准号:
    9796793
  • 财政年份:
    2019
  • 资助金额:
    $ 38.16万
  • 项目类别:
Mechanism of colonization resistance
定植抵抗机制
  • 批准号:
    9110769
  • 财政年份:
    2016
  • 资助金额:
    $ 38.16万
  • 项目类别:
Mechanism of colonization resistance
定植抵抗机制
  • 批准号:
    9332328
  • 财政年份:
    2016
  • 资助金额:
    $ 38.16万
  • 项目类别:
Exacerbation of Colitis by Enterobacteriaceae
肠杆菌科细菌加剧结肠炎
  • 批准号:
    10595010
  • 财政年份:
    2015
  • 资助金额:
    $ 38.16万
  • 项目类别:
Exacerbation of Colitis by Enterobacteriaceae
肠杆菌科细菌加剧结肠炎
  • 批准号:
    10392353
  • 财政年份:
    2015
  • 资助金额:
    $ 38.16万
  • 项目类别:
Mechanism of dysbiosis caused by AE Pathogens
AE病原体引起生态失调的机制
  • 批准号:
    8895812
  • 财政年份:
    2015
  • 资助金额:
    $ 38.16万
  • 项目类别:
Inflammation-derived sugars lower resistance against Salmonella
炎症衍生的糖会降低对沙门氏菌的抵抗力
  • 批准号:
    8974262
  • 财政年份:
    2014
  • 资助金额:
    $ 38.16万
  • 项目类别:
Mechanism of Colonization Resistance
抗殖民化机制
  • 批准号:
    10594972
  • 财政年份:
    2014
  • 资助金额:
    $ 38.16万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 38.16万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 38.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了